2022
Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases
Dohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Yu H, Oliver D, Ahmed K. Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e14. DOI: 10.1016/j.ijrobp.2021.10.186.Peer-Reviewed Original ResearchDistant intracranial controlEGFR-positive NSCLCBrain metastasesRadiation therapyBM diagnosisOverall survivalLocal controlMultivariate analysisSingle-institution retrospective analysisGeneration tyrosine kinase inhibitorsCentral nervous system penetrationUpfront radiation therapyKaplan-Meier methodProportional hazards modelTyrosine kinase inhibitorsMATERIAL/METHODSIntracranial radiation therapyIntracranial controlUpfront treatmentDS-GPAClinical outcomesResults MedianRetrospective analysisTreatment groupsHazards model
2021
Immune Cell Infiltrates of the Tumor Microenvironment and Radiosensitivity of Recurrent Glioblastomas and Their Association With Outcome
Rishi A, Mohammadi H, Martir D, Welsh E, Robinson T, Oliver D, Eschrich S, Torres-Roca J, Yu H, Grass D, Ahmed K. Immune Cell Infiltrates of the Tumor Microenvironment and Radiosensitivity of Recurrent Glioblastomas and Their Association With Outcome. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s123. DOI: 10.1016/j.ijrobp.2021.07.281.Peer-Reviewed Original ResearchImmune cell infiltratesProgression-free survivalAffected overall survivalOverall survivalHelper T cellsRadiosensitivity indexCell infiltrateClinical trialsT cellsPrimary GBMMedian progression-free survivalLack of monocytesNLR/PLRHigh expressionPoor prognostic factorCurrent smoking statusKaplan-Meier estimatesLog-rank testLow-grade gliomasMATERIAL/METHODSAssociation of factorsICI subtypesRGBM patientsAdjuvant radiotherapyFree survivalIn-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Sim A, Figura N, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s131. DOI: 10.1016/j.ijrobp.2021.07.297.Peer-Reviewed Original ResearchMetabolic tumor volumeRefractory large B-cell lymphomaCAR T-cell infusionLarge B-cell lymphomaT-cell infusionT-cell therapyB-cell lymphomaTreatment failureChimeric antigen receptor T-cell therapyField local control rateCAR T-cell therapyBaseline PET/CTLocal failureCAR-T infusionExperience disease progressionLower RT dosesDisease-free survivalLocal control rateMajority of patientsAdequate local controlCAR-T therapyPatterns of failurePET/CTMATERIAL/METHODSCommon regimens